Related Experiment Videos
Peptide aggregation in neurodegenerative disease.
1Department of Chemical Engineering, University of Wisconsin, Madison 53706, USA. murphy@che.wisc.edu
Annual Review of Biomedical Engineering
|July 16, 2002
Summary
Protein aggregates, like beta-amyloid and prions, share similar structures and assembly pathways, offering hope for broad therapeutic strategies against neurodegenerative diseases such as Alzheimer's.
Area of Science:
- Biochemistry
- Neuroscience
- Molecular Biology
Background:
- Protein aggregates were historically dismissed but are now recognized as critical in diseases.
- Focus on beta-amyloid, prion, and huntingtin aggregates linked to Alzheimer's, prion diseases, and Huntington's disease.
Purpose of the Study:
- To review the structural and assembly similarities of protein aggregates.
- To explore potential therapeutic strategies targeting these shared features.
Main Methods:
- Review of existing literature on protein aggregation.
- Analysis of structural data from techniques like X-ray diffraction and solid-state NMR.
- Discussion of proposed protein assembly pathways.
Main Results:
- Despite lacking sequence homology, aggregates of beta-amyloid, prion, and huntingtin share structural traits: high beta-sheet content, fibrillar morphology, insolubility, and protease resistance.
- Similarities exist in proposed assembly pathways, including nucleation-elongation and template-assisted modes.
- Nanometer-resolution structures are challenging to determine due to the noncrystalline nature of aggregates.
Conclusions:
- Shared structural and assembly characteristics of diverse protein aggregates suggest common underlying mechanisms.
- Therapeutic strategies effective against one protein aggregation disease may be applicable to others.
- Further research into aggregate structure and assembly is crucial for developing novel treatments.